WASHINGTON (CBS.MW) -- Procter & Gamble's female testosterone patch has not been studied long enough to determine its long-term health risks, including a possible link to breast cancer, heart disease, and stroke, patient groups told an FDA panel on Thursday. The panel is set to vote on approving the new landmark treatment later in the day. Procter & Gamble did a "small 6-month trial" of its Intrinsa testosterone patch, "but the long-term effects of hormonal therapy might not be known for years," said Anne Kasper, of the patient group Breast Cancer Action. P&G is seeking approval of its patch to treat only surgically menopausal women suffering from reduced sexual desire, but consumer advocates argue that once on the market, the therapy would be misleadingly billed as the female Viagra and would be prescribed beyond that approved use to a much larger population.
(c) 1997-2004 MarketWatch.com, Inc. All rights reserved.